An observational study in Diabetic Retinopathy, sponsored by Eyenuk, Inc.. Completed at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2022-11-09.
Sponsored by Eyenuk, Inc. · Observational
The study evaluates the performance of the EyeArt system for detecting diabetic retinopathy from images captured using retinal cameras and operators.
773 studies on the registry are indexed under Diabetic Retinopathy; 139 are open to participants now.
This study's enrollment of 246 is above the median of 154 across 264 observational studies indexed under Diabetic Retinopathy.
Browse Diabetic Retinopathy studies →Eyenuk, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Study subjects will be enrolled at primary care and/or eye care centers
Exclusion Criteria:
Procedure: Retinal imaging · Drug: Mydriatic Agent
Subjects will undergo retinal imaging before and/or after administration of mydriatic agent
Subjects will be administered mydriatic medication to dilate their pupils.
Overall agreement between the results from multiple EyeArt operations
Overall agreement is defined as the fraction of cases where the multiple EyeArt operation results agree with each other.
Time frame: 1 visit (1 day)
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eyenuk, Inc.